在治疗耐药性抑郁症患者中,灵活使用 псилоцибин剂量的新证据
Scott T Aaronson1, Zofia Kozak2
1Institute for Advanced Diagnosis and Therapeutics, Sheppard Pratt Hospital System, Baltimore, MD, USA; University of Maryland School of Medicine, Department of Psychiatry, Baltimore, MD, USA.
Med (New York, N.Y.)
|February 15, 2024
概括
西治疗对严重抑郁症有很大的前景. 一个灵活的剂量试验包括患有复杂疾病的患者,如双相二极性障碍,表明更广泛的治疗潜力.
科学领域:
- 心理药理学 心理药理学
- 神经科学是一个神经科学.
- 临床精神病学 临床精神病学
背景情况:
- 西在治疗抑郁症方面显示出有效性.
- 之前的临床试验排除了精神复杂的患者.
- 关于治疗耐药性抑郁症 (TRD) 与并发症治疗的 псилоцибин的数据有限.
研究的目的:
- 评估灵活的西剂量表的可行性.
- 为了评估严重TRD患者的psilocybin的潜力.
- 探索psilocybin在患有并发疾病的患者中使用的可能性,包括双极性II障碍 (BPII).
主要方法:
- 进行了一项临床试验,对被诊断患有严重TRD的个人进行了试验.
- 施用了灵活的 псилоцибин剂量计划.
- 包括患有并发性疾病和BPII的患者.
主要成果:
- 研究人员发现,灵活的西剂量计划是可行的.
- 包括患有TRD,并发病症和BPII的患者证明了可行性.
- 这种方法可能会扩大西治疗模式.
结论:
- 在严重的TRD患者中,灵活的psilocybin剂量是可行的,即使是复杂的条件.
- 这项研究支持对更广泛的患者群体进行进一步的psilocybin调查.
- 西治疗可能为患有耐治疗抑郁症和并发性疾病的个人提供一个新的途径.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
230
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
230
Electroconvulsive Therapy
39
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
39
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170


